The drug makers that are likely to be hit directly by the development include Natco, Sun Pharmaceuticals, Ranbaxy, Cipla, Intas and Camlin Pharma who have already launched a form of this drug. Novartis will enjoy five years of exclusive marketing right for the drug from the date of approval.
Ranjit Shahani, vice-chairman and managing director Novartis India said,
